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Flow synthesis of ethyl isocyanoacetate enabling
the telescoped synthesis of 1,2,4-triazoles and
pyrrolo-[1,2-c]pyrimidines†
Marcus Baumann,a Antonio M. Rodriguez Garciaa,b and Ian R. Baxendale*a
The eﬃcient ﬂow synthesis of important heterocyclic building blocks based on the 1,2,4-triazole and
pyrrolo[1,2-c]pyrimidine scaﬀold has been achieved. Crucially, a telescoped continuous ﬂow process was
developed based on the reaction of N-formylglycine with triphosgene to deliver a stream of ethyl iso-
cyanoacetate in situ, which subsequently yielded the desired heterocyclic entities in a telescoped reac-
tion. Additionally, the functionalisation of the pyrrolo[1,2-c]pyrimidine core via subsequent SEAr reactions
was studied revealing insight into a ‘halogen dance’ phenomenon associated with these medicinally rele-
vant architectures.
Introduction
The eﬃcient preparation of novel heterocyclic building blocks
functionalised with suitable derivatisation sites is of para-
mount importance to the successful discovery of new bioactive
molecules.1 Certainly the most eﬀective pharmaceutical and
agrochemical strategy for the generation of propriety leads is
through screening of diverse core structures, which upon stra-
tegic functionalisation engenders desirable physiological pro-
perties and yields focused libraries of advanced drug-like
structures. Consequently, the conformational presentation dis-
played by the core template impacts strongly on the available
binding and contact points that can be interacted upon within
the biological environment. It is therefore not surprising that
most of today’s top-selling drugs contain at least one hetero-
cyclic core often acting as its pharmacophore.2 In order to
eﬃciently access new chemical scaﬀolds medicinal chemists
have been increasingly exploiting enabling technologies to
allow access to novel chemical space.3 Amongst these techno-
logies flow chemistry approaches have gained widespread
acceptance as a powerful means to overcome limitations
regarding scale-up, reproducibility, safety and accessible
chemical space with numerous publications detailing the
results of such studies.4
One particular area where flow chemistry has led to signifi-
cantly improved safety profiles compared to traditional batch
synthesis is the in situ generation and subsequent use of
highly reactive, yet hazardous species. Examples include, but
are not limited to, the generation and use of ozone,5 azides,6
diazonium species,7 or elemental fluorine8 as well as cryo-
genic9 or high temperature10 reactions.
In this paper we wish to disclose our latest results towards
the flow synthesis of valuable heterocyclic architectures such
as 1,2,4-triazoles and pyrrolo[1,2-c]pyrimidines based on the in
situ generation of ethyl isocyanoacetate through the dehy-
dration of N-formylglycine using reactive triphosgene
(Scheme 1).
Results and discussion
Synthesis of ethyl isocyanoacetate in flow
Ethyl isocyanoacetate (3) is a commercially available high
boiling liquid characterised by its pungent odour as well as its
sensitivity towards light and moisture. Despite this it is fre-
Scheme 1 Multi-step ﬂow approach towards valuable heterocyclic
scaﬀolds.
†Electronic supplementary information (ESI) available. CCDC 1039437, 1039438,
1039439, 1039440 and 1039441. For ESI and crystallographic data in CIF or other
electronic format see DOI: 10.1039/c5ob00245a
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quently used as a key building block in multicomponent reac-
tions and heterocycle synthesis.11 Because of these features we
decided to develop a convenient in situ flow synthesis of ethyl
isocyanoacetate starting from readily available N-formylglycine
(1).12 As the dehydrating agent we choose triphosgene (2), a
commercially available crystalline solid.13 This material is not
only easier to handle than many other dehydrating agents (e.g.
COCl2, POCl3, SOCl2 etc.), but also comprises three equivalents
of active dehydrating agent per molecule. Furthermore, only
HCl and CO2 are generated as by-products through its use. In
an initial study we used a commercially available R2+ Vapour-
tec flow reactor which was configured to mix two reagent
streams via a T-piece: stream A contained N-formylglycine
(DCM, 0.25 M, 1.0 equiv.), DIPEA (2 equiv.) and DMAP (0.3
equiv.) and stream B contained triphosgene (DCM, 0.0875 M,
0.35 equiv.). Using 1H-NMR analysis of aliquots of the product
stream it was quickly established that the desired ethyl iso-
cyanoacetate forms almost quantitatively at room temperature
within a 20 min residence time (Scheme 2).
Synthesis of 1,2,4-triazoles in flow
Having developed an eﬃcient protocol for the synthesis of
ethyl isocyanoacetate in flow, we next turned our attention to
its reaction with various aryl diazonium species, also prepared
in situ, to furnish a convergent synthesis of 1,2,4-triazoles.14
To facilitate the reaction, four stock solutions (solutions
1–4) were prepared, along with a small collection of aniline
starting materials (solution 5). To perform the multi-step flow
sequence an integrated flow reactor configured as shown in
Scheme 3 was constructed. This comprised a Uniqsis FlowSyn
with an ALF delivery and control system, a Vapourtec R2+/R4
unit, two auxiliary Knauer K100 HPLC pumps and two Polar
bear plus flow reactors (see ESI† for additional details). Using
this setup a continuous flow stream of intermediate 3 was pre-
pared as described (see above) and was united with a solution
containing the corresponding diazonium coupling partner 6
as a convergent assembly process.
The diazonium component 6 was readily prepared from the
precursor aniline or its mono-hydrochloride salts (in MeCN)
by treatment with tert-butyl nitrite at ambient temperature.15
For the subsequent cycloaddition reaction the two flow
streams containing 3 and 6 were combined and then in succes-
sion diluted with a stream of pure ethanol and treated with an
aqueous feed of potassium carbonate (5 equiv.). A static mixer
was placed in-line to thoroughly blend the flow stream before
it passed into a heated reaction coil maintained at 75 °C. The
reactor output was collected and worked up by evaporation of
the solvent followed by neutralisation with dilute hydrochloric
acid and partitioning into ethyl acetate. The products were iso-
lated in high yield and purity after solvent evaporation and tri-
turation of the crude product with a mixture of diethyl ether–
ethanol 15 : 1. Pleasingly the above flow protocol proved
general and was applied to the synthesis of a small selection
of 1,2,4-triazole products (7a–h) (Fig. 1).
Derivatisation of 1,2,4-triazoles
In order to briefly evaluate the feasibility of these [1,2,4]-tri-
azoles (7a–h) to serve as building blocks towards future research
eﬀorts we decided to specifically study the functionalisation of
the 5-position of the heterocyclic core. To this end regioselec-
tive bromination was aﬀected by treating 7h with a mixture of
NaH and NBS in dry THF16 (Scheme 4). Pleasingly, after 10 h
reaction time, complete consumption of the starting material
and clean formation of the desired product 8 was observed.
After purification 8 was subjected to a small number of Suzuki
cross coupling reactions in order to synthesise 9a–e.17
Although this reaction required prolonged reaction times at
elevated temperatures (8–10 h at 120 °C) the desired Suzuki
cross coupling products were formed chemoselectively and iso-
lated in reasonable yield allowing further eﬀorts to be directed
towards the diversification of these scaﬀolds.
Synthesis of pyrrolo[1,2-c]pyrimidines in flow
After accomplishing a successful multi-step flow synthesis of
various 1,2,4-triazoles we decided to diversify the protocol
towards the synthesis of another underexploited scaﬀold – the
pyrrolo[1,2-c]pyrimidine. This structure has shown value for
example as the core structure of various nicotinic acetylcholine
receptor agonists developed to treat CNS disorders18 and can
be prepared by reacting ethyl isocyanoacetate with readily avail-
able pyrrole-2-carboxaldehyde.19 After a short optimisation
study we found that treatment of a flow stream of ethyl iso-
cyanoacetate with a secondary stream containing pyrrole-2-
carboxaldehyde (10, 0.25 M, 1.0 equiv.) and piperidine
Scheme 2 Flow synthesis of ethyl isocyanoacetate (Reactor ﬂow
pathway left to right).
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(6 equiv.) in DCM aﬀorded the desired pyrrolo[1,2-c]pyrimidine
structure 11 after passing through a flow coil maintained at
slightly elevated temperature (85 °C, 26 min residence time,
Scheme 5; Fig. 2).
In order to avoid any issues of precipitate formation within
the flow system (i.e. piperidine-HCl salts) a working concen-
tration of 0.25 M was targeted resulting in a theoretical
throughput of 5.71 g h−1. The desired pyrrolo[1,2-c]pyrimidine
product could be isolated in 85% yield and high purity (>95%
by 1H-NMR) as a beige solid after extraction and evaporation of
the volatiles. This crude material was of suﬃcient quality to be
used in further reactions however an analytical sample was
Fig. 1 Representative [1,2,4]-triazoles prepared in ﬂow.
Scheme 4 Functionalization study of triazole 7h.
Scheme 3 Multi-step ﬂow approach towards 1,2,4-triazoles.
Scheme 5 Multi-step ﬂow approach towards pyrrolo[1,2-c]pyrimidine.
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further purified by column chromatography to furnish a yellow
solid (78%). The reactor could be run under semi-continuous
operation delivering ∼30 g over the course of a standard
working day (8 h) including start-up/shut down and cleaning
of the system.
Having established convenient access to multigram quan-
tities of this pyrrolo[1,2-c]pyrimidine core (11) we decided to
evaluate its functionalisation via electrophilic aromatic substi-
tution reactions. Specifically we intended to establish whether
this scaﬀold could be decorated in a regioselective manner
allowing access to versatile architectures for future synthesis
programmes. We therefore performed a number of Density
Functional Theory (DFT) calculations to compare the inter-
mediates originating from addition to the most likely C7 and
C5 positions of the pyrrole subunit (Scheme 6, Table 1). The
geometries of the species were optimised with the 6-311++G
(2df,2pd) basis set (for iodine the cc-pVTZ-PP basis set20 with
the Stuttgarts pseudopotential21 was used) employing Truhlar
functionals, M06-2X,22 which have been shown to successfully
describe the thermochemistry, kinetics, and noncovalent inter-
actions of such systems. The computational calculations were
performed using Gaussian 09 program suite;23 frequency ana-
lysis was also performed to confirm the nature of the station-
ary points and to obtain zero-point energies (ZPEs). Solvent
eﬀects on molecular geometries and energies were estimated
by means of Polarization Continuum Models (PCM)24 with
DCM as the solvent.
The data correlated in Table 1, implies a distinct kinetic
preference for reaction at the C7 over C5 position due to
enhanced delocalisation into the adjacent ring, however the
most stable products are those with substitution at C5. Further
DFT studies, also confirmed the nucleophilic character of the
specified C5 and C7 positions of the pyrrolo[1,2-c]pyrimidine
(Fig. 3). We were therefore confident that a regioselective func-
tionalisation of the pyrrolopyrimidine could be achieved.
We subsequently prepared a number of pyrrolo[1,2-c]pyri-
midine derivatives (12a–i) confirming that the most reactive
site was indeed the C7 position of the pyrrole moiety followed
by the C5 position. This analysis was largely enabled by single
crystal X-ray diﬀraction experiments as 1H- and 13C-NMR
experiments were not always conclusive (Scheme 7).
Whilst this strategy allowed for the eﬃcient and regioselec-
tive monofunctionalisation at C7 via halogenation (Cl, Br. I),
formylation and acetylation reactions, it was noted that the
subsequent introduction of a second electrophilic substituent
did not always furnish the predicted product.
The nitration or bromination of the chlorinated pyrrolo[1,2-c]-
pyrimidine intermediate did yield the expected reaction products
Fig. 2 Flow reactor used for the synthesis of pyrrolo[1,2-c]pyrimidine.
Scheme 6 General schematic of the DFT calculations performed on
the electrophilic attack on the pyrrolopyrimidine moiety.
Table 1 Collected Gibbs free energies on the structures
Entry Compound
ΔG (Kcal mol−1) M06-2x/
6-311++G(2df,2pd)
INTa PRODa
1 5-Cl 3.23 −1.92
2 7-Cl 0.00 0.00
3 5-Br 1.62 −0.86
4 7-Br 0.00 0.00
5 5-I 0.76 −1.39
6 7-I 0.00 0.00
a The energies are all reported relative to the 7-halo compounds which
were the thermodynamic control compounds.
Fig. 3 Dual descriptor Fukui function of pyrrolo[1,2-c]pyrimidine (11).
(green electrophilic regions; blue nucleophilic regions).
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12a and 12b. However, preparation of the dihalo-structure 12c
was only possible when halogenating (use of NBS or NCS)
under neutral conditions. Conducting the chlorination step in
the presence of HCl or for prolonged reaction times (i.e. >10 h)
resulted in the formation of a mixture of 12b and 12c.
Additionally, when attempting nitration of substrate 8 it
was noted that a mixture of two mono-nitrated products as
well as the di-nitrated scaﬀold 12d formed very rapidly.
Furthermore, attempted nitration of the 7-mono-iodinated
pyrrolo[1,2-c]pyrimidine core yielded a mixture of nitrated pro-
ducts (12h, 12i) that after longer reaction time (12 h) would
also generate small quantities (∼15%) of the previously pre-
pared di-nitrated product 12d. As the identity of 12i had been
confirmed by single crystal X-ray diﬀraction experiments, we
suggest the occurrence of a ‘halogen dance’ phenomenon in
cases where brominated or iodinated monofunctionalisation
products are subjected to a second SEAr reaction under
strongly acidic conditions. We thus propose that under acidic
conditions the second electrophile is again first introduced at
C7 generating a tetrahedral intermediate 13b (Scheme 8). This
structure can then undergo a [1,3]-shift in which the most
weakly bound halogen migrates to the 5-position of the pyrrolo
[1,2-c]pyrimidine scaﬀold (i.e. 13c) thus resembling other
‘halogen dance’ phenomena reported in the literature.25
Overall, the strategic use of this rearrangement could lead to
otherwise diﬃcult to access structures and thus opens avenues
towards specifically functionalised pyrrolo[1,2-c]pyrimidine
scaﬀolds. Further research is now required to fully evaluate
and develop these initial findings.
Conclusions
In conclusion, we have successfully developed a valuable flow
protocol for the synthesis of ethyl isocyanoacetate via dehy-
dration of N-formylglycine using triphosgene. The versatility of
generating this isocyanide building block in situ was further
exploited by multi-step sequences towards various 1,2,4-tri-
azoles as well as the pyrrolo[1,2-c]pyrimidine scaﬀold, whose
further functionalisation by means of SEAr reactions has been
demonstrated. These studies have also allowed insights in the
occurrence of halogen dance phenomena during the elabor-
ation of the pyrrolo[1,2-c]pyrimidine scaﬀold. We believe that
this study demonstrates the benefits of modern flow tech-
niques in the generation and use of hazardous, yet versatile
intermediates towards medicinally relevant structures.
Experimental section
General experimental section
1H-NMR spectra were recorded on either Bruker Avance-400,
Varian VNMRS-600 or Varian VNMRS-700 instruments and are
reported relative to residual solvent: CHCl3 (δ 7.26 ppm) or
DMSO (δ 2.50 ppm). 13C-NMR spectra were recorded on the
same instruments and are reported relative to CHCl3
(δ 77.16 ppm) or DMSO (δ 39.52 ppm). Data for 1H-NMR are
reported as follows: chemical shift (δ/ppm) (integration, multi-
plicity, coupling constant (Hz)). Multiplicities are reported as
follows: s = singlet, d = doublet, t = triplet, q = quartet, p =
pentet, m = multiplet, br. s = broad singlet, app = apparent.
Data for 13C-NMR are reported in terms of chemical shift
(δ/ppm) and multiplicity (C, CH, CH2 or CH3). Data for
19F-NMR were recorded on the above instruments at a fre-
quency of 376 MHz using CFCl3 as external standard.
DEPT-135, COSY, HSQC, HMBC and NOESY experiments were
used in the structural assignment. IR spectra were obtained by
use of a Perkin Elmer RX1 spectrometer (neat, ATR sampling)
Scheme 7 Functionalization of the pyrrolo[1,2-c]pyrimidine core by
SEAr reactions (overall isolated yields for 2 steps).
Scheme 8 Proposed mechanism for ‘halogen dance’ under acidic
conditions.
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with the intensities of the characteristic signals being reported
as weak (w, <20% of tallest signal), medium (m, 21–70% of
tallest signal) or strong (s, >71% of tallest signal). Low and
high resolution mass spectrometry was performed using the
indicated techniques on either Waters LCT Premier XE or
Waters TQD instruments equipped with Acquity UPLC and a
lock-mass electrospray ion source. For accurate mass measure-
ments the deviation from the calculated formula is reported in
ppm. Melting points were recorded on an Optimelt automated
melting point system with a heating rate of 1 °C min−1 and
are uncorrected.
Single crystal X-ray data were collected at 120.0 K on a
Bruker SMART 6000 (sealed tube, graphite monochromator)
(compounds 7h and SI12f′) and Bruker D8 Venture (Photon
100 CMOS detector, IμS microsource, focusing mirrors) (com-
pounds 12a, 12f and 12i) diﬀractometers (λMoKα, λ =
0.71073 Å) equipped with Cryostream (Oxford Cryosystems)
open flow nitrogen cryostates. The structures were solved by
direct methods and refined by full-matrix least squares on F2
for all data using SHELX26 and OLEX227 software. All non-
hydrogen atoms were refined with anisotropic displacement
parameters, the H-atoms in the structures 12a, 12f and 12i
were placed in calculated positions and refined in “riding”
mode. The H atoms in the other structures were found in the
diﬀerence Fourier maps and refined isotropically. Crystallo-
graphic data and parameters of the refinement are given in
Table 1 (ESI†). Crystallographic data for the structures have
been deposited with the Cambridge Crystallographic Data
Centre as supplementary publication CCDC-1039437–1039441.
Ethyl 1-(3-chloro-4-fluorophenyl)-1H-1,2,4-triazole-3-carboxy-
late, 7a. 71%: Mp 186.3–187.9 °C (decomposed). Compound
description: tan solid.1H NMR (400 MHz, DMSO-d6) δ 9.46 (s,
1H), 8.23 (dd, J = 6.4, 2.7 Hz, 1H), 7.95 (ddd, J = 9.0, 4.2, 2.7
Hz, 1H), 7.69 (t, J = 9.0 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.34 (t,
J = 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 159.6 (C),
157.3 (d, J = 248.6 Hz, CF), 155.2 (C), 145.0 (CH), 133.8 (d, J =
3.4 Hz, C), 122.9 (CH), 121. 5 (d, J = 8.0 Hz, CH), 121.2 (d, J =
19.0 Hz, C), 118.6 (d, J = 22.7 Hz, CH), 61.9 (CH2), 14.5 (CH3).
19F NMR (376 MHz, DMSO-d6) δ −116.21 (s). IR (neat):
ν 3116.9 (m), 1721.4 (s), 1511.9 (m), 1493.3 (s), 1451.0 (s),
1339.7 (m), 1252.7 (s), 1202.1 (s), 1089.1 (s), 1051.9 (m),
996.6 (s), 849.9 (s), 828.2 (s), 718.9 (s), 667.6 (s), 639.4 (s) cm−1.
LC-MS (ESI): 292.1 (M + Na); HRMS (ESI): calculated
for C11H10N3O2ClF 270.0446, found 270.0443 (M + H, Δ =
−0.3 ppm).
Ethyl 1-(m-tolyl)-1H-1,2,4-triazole-3-carboxylate, 7b. 68%:
Mp 80.2–81.5 °C. Compound description: brown powder. 1H
NMR (400 MHz, DMSO-d6) δ 9.43 (s, 1H), 7.74 (dt, J = 1.6, 0.8
Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.29
(d, J = 7.8 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 3.36 (s, 1H), 1.34 (t,
J = 7.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 159.8 (C),
155.0 (C), 144.4 (CH), 140.1 (C), 136.7 (C), 130.1 (CH), 129.7
(CH), 120.8 (CH), 117.4 (CH), 61.8 (CH2), 21.3 (CH3), 14.6
(CH3). IR (neat): 3109.9 (w), 1715.6 (s), 1497.7 (m), 1448.3 (s),
1255.8 (s), 1194.4 (s), 1081.8 (s), 1015.9 (s), 886.1 (m), 848.6
(m), 792.5 (s), 669.4 (s) cm−1. LC-MS (ESI): 254.1 (M + Na);
HRMS (ESI): calculated for C12H14N3O2 232.1086, found
232.1084 (M + H, Δ = −0.2 ppm).
Ethyl 1-(3-methoxyphenyl))-1H-1,2,4-triazole-3-carboxylate,
7c. 53%: Mp 97.4 °C (decomposed). Compound description:
dark brown solid. 1H NMR (400 MHz, DMSO-d6) δ 9.47 (s, 1H),
7.60–7.38 (m, 3H), 7.06 (ddd, J = 8.0, 2.6, 1.9 Hz, 1H), 4.38 (q,
J = 7.1 Hz, 2H), 3.86 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 160.7 (C), 159.7 (C), 155.0 (C), 144.6
(CH), 137.8 (C), 131.3 (CH), 114.9 (CH), 112.4 (CH), 106.0 (CH),
61.8 (CH2), 56.1 (CH3), 14.6 (CH3). IR (neat): 3106.8 (w), 1730.3
(s), 1607.5 (m), 1504.9 (s), 1469.9 (s), 1281.3 (s), 1240.8 (s),
1193.7 (s), 1174.4 (s), 1029.4 (s), 992.2 (s), 882.3 (s), 772.0 (s),
669.4 (s) cm−1. LC-MS (ESI): 270.1 (M + Na); HRMS (ESI):
calculated for C12H14N3O3 248.1035, found 248.1035 (M + H,
Δ = 0.0 ppm).
Ethyl 1-(3-fluorophenyl))-1H-1,2,4-triazole-3-carboxylate,
7d. 62%: Mp 214.3 °C (decomposed). Compound description:
pale tan solid. 1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H),
7.84 (dt, J = 10.0, 2.3 Hz, 1H), 7.79 (ddd, J = 8.0, 2.3, 0.9 Hz,
1H), 7.65 (td, J = 8.3, 6.2 Hz, 1H), 7.36 (tdd, J = 8.4, 2.6, 0.9 Hz,
1H), 4.39 (q, J = 7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR
(101 MHz, DMSO-d6) δ 162.8 (d, J = 245.2 Hz, CF), 159.6 (C),
155.2 (C), 144.9 (CH), 138.0 (d, J = 10.6 Hz, C), 132.3 (d, J = 9.2
Hz, CH), 116.4 (d, J = 3.1 Hz, CH), 115.9 (d, J = 21.1 Hz, CH),
108.0 (d, J = 26.8 Hz, CH), 61.9 (CH2), 14.5 (CH3).
19F NMR
(376 MHz, DMSO-d6) δ −110.60 (s). IR (neat): 3102.2 (w),
1719.8 (s), 1606.1 (s), 1496.3 (s), 1449.2 (s), 1341.6 (m), 1260.4
(s), 1199.4 (s), 1004.4 (m), 862.5 (s), 783.3 (s), 667.9 (s) cm−1.
LC-MS (ESI): 258.1 (M + Na); HRMS (ESI): calculated for
C11H11N3O2F 236.0835, found 236.0835 (M + H, Δ = 0.0 ppm).
Ethyl 1-(3-(trifluoromethyl)phenyl))-1H-1,2,4-triazole-3-carboxy-
late, 7e. 55%: Mp 129.3–130.4 °C. Compound description:
orange powder. 1H NMR (400 MHz, DMSO-d6) δ 9.61 (s, 1H),
8.30 (br s, 1H), 8.28–8.20 (m, 1H), 7.92–7.80 (m, 2H), 4.40 (q,
J = 7.1 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 159.6 (C), 155.3 (C), 145.1 (CH), 137.3 (C), 131.8
(CH), 130.94 (q, J = 32.5 Hz, C), 125.7 (q, J = 3.7 Hz, CH), 124.4
(CH), 124.0 (q, J = 273.6 Hz, CF3), 117.14 (q, J = 4.0 Hz, CH),
61.9 (CH2), 14.5 (CH3).
19F NMR (376 MHz, DMSO-d6) δ −61.2
(s). IR (neat): 3107.7 (w), 1719.8 (m), 1450.6 (s), 1316.3 (s),
1255.2 (s), 1163.7 (s), 1116.5 (s), 1081.5 (s), 995.1 (m), 902.9
(m), 807.4 (s), 698.8 (s), 668.4 (s) cm−1. LC-MS (ESI): 308.1
(M + Na); HRMS (ESI): calculated for C12H11N3O2F3 286.0803,
found 286.0795 (M + H, Δ = −2.8 ppm).
Ethyl 1-(4-bromophenyl))-1H-1,2,4-triazole-3-carboxylate,
7f. 69%: Mp 152.4–143.8 °C. Compound description: white
crystalline solid. 1H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H),
7.89 (d, J = 8.9 Hz, 2H), 7.82 (d, J = 8.9 Hz, 2H), 4.38 (q, J =
7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 159.6 (C), 155.2 (C), 144.7 (CH), 136.0 (C), 133.2
(2CH), 122.4 (2CH), 121.8 (C), 61.9 (CH2), 14.6 (CH3). IR (neat):
3133.7 (w), 1718.4 (s), 1483.9 (s), 1451.2 (s), 1338.4 (m),
1257.5 (s), 1203.3 (s), 1067.0 (s), 1029.4 (m), 979.8 (s), 826.9 (s),
668.3 (s) cm−1. LC-MS (ESI): 318.0 (M + Na); HRMS (ESI): calcu-
lated for C11H11N3O2Br 296.0035, found 296.0036 (M + H,
Δ = +0.1 ppm).
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Ethyl 1-(3-chlorophenyl))-1H-1,2,4-triazole-3-carboxylate,
7g. 68%: Mp 114.6–115.5 °C. Compound description: orange
powder. 1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 8.06 (t,
J = 2.0 Hz, 1H), 7.90 (ddd, J = 8.1, 2.1, 1.1 Hz, 1H), 7.64 (t, J =
8.1 Hz, 1H), 7.57 (ddd, J = 8.1, 2.0, 1.0 Hz, 1H), 4.39 (q, J =
7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 159.6 (C), 155.2 (C), 144.9 (CH), 137.9 (C),
134.6 (C), 132.1 (CH), 128.9 (CH), 120.3 (CH), 119.1 (CH),
61.9 (CH2), 14.5 (CH3). IR (neat): 3109.6 (w), 1719.9 (s),
1595.0 (m), 1485.9 (m), 1450.6 (s), 1341.9 (m), 1256.3 (s),
1198.1 (s), 1103.1 (s), 1079.9 (s), 1028.7 (s), 993.6 (s), 892.9 (s),
846.7 (m), 792.0 (s), 769.0 (s), 667.4 (s) cm−1. LC-MS (ESI):
274.0 (M + Na); HRMS (ESI): calculated for C11H11N3O2Cl
252.0540, found 252.0535 (M + H, Δ = −0.5 ppm).
Ethyl 1-(4-chlorophenyl))-1H-1,2,4-triazole-3-carboxylate,
7h. 67%: Mp 136.5–137.0 °C. Compound description: white
crystalline solid. 1H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H),
7.95 (d, J = 8.9 Hz, 2H), 7.68 (d, J = 8.9 Hz, 2H), 4.38 (q, J =
7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz,
DMSO-d6) δ 159.6 (C), 155.2 (C), 144.7 (CH), 135.6 (C),
133.4 (C), 130.3 (2CH), 122.2 (2CH), 61.9 (CH2), 14.6 (CH3).
IR (neat): 3125.9 (w), 1725.3 (m), 1487.3 (s), 1450.4 (s),
1339.4 (m), 1257.5 (s), 1202.6 (s), 1074.8 (s), 1028.0 (m), 981.5
(s), 831.2 (s), 668.4 (m) cm−1. LC-MS (ESI): 274.1 (M + Na);
HRMS (ESI): calculated for C11H11N3O2Cl 252.0540, found
252.0541 (M + H, Δ = +0.1 ppm). CCDC 1039438.
Ethyl 7-chloro-5-nitropyrrolo[1,2-c]pyrimidine-3-carboxylate,
12a. 72%, Mp 145 °C (decomposition). Compound descrip-
tion: brown solid. 1H NMR (600 MHz, CDCl3) δ 9.06 (s, 1H),
8.96 (s, 1H), 7.51 (s, 1H), 4.50 (q, J = 7.2 Hz, 2H), 1.45 (t, J =
7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 163.3 (C), 138.6 (C),
135.5 (CH), 129.0 (C), 127.9 (C), 115.5 (CH), 112.5 (CH), 111.5
(C), 62.6 (CH2), 14.3 (CH3). IR (neat): 3132.5 (w), 1727.3 (s),
1617.9 (w), 1481.0 (s), 1425.5 (m), 1406.5 (m), 1314.6 (s),
1221.6 (s), 1127.7 (s), 1101.3 (s), 1010.2 (m), 973.6 (m),
848.4 (m), 783.7 (s), 759.6 (m) cm−1. LC-MS (ESI): 270.1.0
(M + H); HRMS (ESI): calculated for C10H9N3O4Cl 270.0282,
found 270.0287 (M + H, Δ = 1.9 ppm). CCDC 1039441.
Ethyl 5-bromo-7-chloropyrrolo[1,2-c]pyrimidine-3-carboxy-
late, 12b. 83%, Mp 109.1–113.0 °C. Compound description:
Beige solid. 1H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 1.6 Hz,
1H), 8.15 (d, J = 1.6 Hz, 1H), 6.91 (s, 1H), 4.46 (q, J = 7.2 Hz),
1.44 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 164.4 (C),
134.8 (CH), 131.4 (C), 128.7 (C), 117.7 (CH), 115.6 (CH), 110.1
(C), 92.5 (C), 61.9 (CH2), 14.4 (CH3). IR (neat): 1699.8 (s),
1524.7 (m), 1445.7 (m), 1422.2 (m), 1368.0 (m), 1288.4 (s),
1232.1 (s), 1086.4 (m), 1019.8 (m), 813.1 (m), 776.5 (s), 711.1
(m), 593.5 (s) cm−1. LC-MS (ESI): 303.4 (M + H); HRMS (ESI):
calculated for C10H9N2O2ClBr 302.9536, found 302.9541
(M + H, Δ = 1.7 ppm).
Ethyl 5-chloro-7-bromopyrrolo[1,2-c]pyrimidine-3-carboxy-
late, 12c. 79%, Mp 110 °C (decomposition). Compound
description: brown solid. 1H NMR (400 MHz, CDCl3) δ 8.75 (d,
J = 1.2 Hz, 1H), 8.14 (d, J = 1.2 Hz, 1H), 6.91 (s, 1H), 4.44 (q, J =
7.2 Hz, 2H), 1.42 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ 164.4 (C), 136.0 (CH), 131.1 (C), 128.6 (C), 119.1 (CH),
114.6 (CH), 108.7 (C), 94.4 (C), 61.9 (CH2), 14.4 (CH3).
IR (neat): 1701.2 (s), 1524.6 (m), 1420.1 (m), 1361.7 (m), 1313.0
(m), 1283.0 (s), 1243.8 (s), 1091.9 (m), 1017.4 (m), 821.5 (s),
774.8 (s), 711.5 (s), 594.5 (s) cm−1. LC-MS (ESI): 324.9 (M + Na);
HRMS (ESI): calculated for C10H8N2O2ClBrNa 324.9355, found
324.9358 (M + Na, Δ = 0.9 ppm).
Ethyl 5,7-dinitropyrrolo[1,2-c]pyrimidine-3-carboxylate,
12d. 90%, Mp 100.8–103.3 °C. Compound description: yellow-
brown solid. 1H NMR (400 MHz, CDCl3) δ 10.37 (d, J = 1.2 Hz,
1H), 9.18 (d, J = 1.2 Hz), 8.46 (s, 1H), 4.55 (q, J = 7.2 Hz, 2H),
1.49 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 162.4 (C),
142.3 (C), 138.1 (CH), 131.7 (C), 129.5 (C), 127.6 (C),
115.8 (CH), 115.5 (CH), 63.2 (CH2), 14.3 (CH3). IR (neat):
1729.3 (s), 1500.8 (m), 1475.7 (m), 1334.1 (s), 1239.2 (s),
1139.2 (m), 1005.6 (s), 815.4 (m), 784.7 (s), 764.2 (s), 735.8 (s),
611.0 (m) cm−1. LC-MS (ESI): 303.4 (M + Na); HRMS (ESI):
calculated for C10H9N4O6 281.0522, found 281.0510 (M + H,
Δ = −4.3 ppm).
Ethyl 5,7-dibromopyrrolo[1,2-c]pyrimidine-3-carboxylate,
12e. 92%, Mp 113.8–115.5 °C. Compound description: brown
solid. 1H NMR (400 MHz, CDCl3) δ 8.68 (d, J = 1.6 Hz, 1H),
7.99 (d, J = 1.6 Hz, 1H), 6.88 (s, 1H), 4.39 (q, J = 7.2 Hz, 2H),
1.37 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 164.3 (C),
136.1 (CH), 131.5 (C), 130.2 (C), 121.1 (CH), 115.2 (CH), 95.1
(C), 93.2 (C), 61.8 (CH2), 14.4 (CH3). IR (neat): 1700.7 (s),
1521.5 (w), 1416.9 (s), 1345.0 (s), 1281.7 (s), 1241.1 (s), 1016.2
(s), 823.4 (s), 775.1 (s), 710.9 (s), 593.4 (s) cm−1. LC-MS (ESI):
346.8 (M + H); HRMS (ESI): calculated for C10H9N2O2Br2
346.9031, found 346.9015 (M + H, Δ = −4.6 ppm).
Ethyl 5-bromo-7-(2,2,2-trifluoroacetyl)pyrrolo[1,2-c]pyrimi-
dine-3-carboxylate, 12f. 73%, Mp 106.8–108.3 °C. Compound
description: beige solid. 1H NMR (400 MHz, CDCl3) δ 10.38 (d,
1H, J = 1.6 Hz), 8.38 (d, 1H, J = 1.6 Hz), 7.86 (q, 1H, J = 2.0 Hz),
4.51 (q, 2H, J = 7.2 Hz), 1.46 (t, 3H, J = 7.2 Hz). 13C NMR
(101 MHz, CDCl3) δ 169.4 (q, J = 37 Hz, C), 163.4 (C), 140.0
(CH), 139.3 (C), 137.9 (C), 129.0 (q, J = 4 Hz, CH), 118.2 (C),
119.5 (q, J = 290 Hz, CF3), 115.1 (CH), 95.9 (C), 62.7 (CH2), 14.3
(CH3).
19F NMR (376 MHz, CDCl3) δ −71.71 (s). IR (neat):
3086.2 (w), 1736.3 (m), 1662.6 (m), 1351.1 (m), 1214.0 (m),
1155.6 (s), 1098.0 (s), 906.3 (m), 851.2 (m), 756.7 (m), 657.6 (m)
cm−1. LC-MS (ESI): 386.9 (M + Na); HRMS (ESI): calculated for
C12H9N2O3BrF3 364.9749, found 364.9750 (M + H, Δ =
0.3 ppm). CCDC 1039439.
Ethyl 5-iodo-7-formylpyrrolo[1,2-c]pyrimidine-3-carboxylate,
12g. 77%, Mp 205 °C (decomposition). Compound descrip-
tion: yellow solid. 1H NMR (400 MHz, CDCl3) δ 10.23 (d, J = 1.2
Hz, 1H), 9.86 (s, 1H), 8.27 (d, J = 1.2 Hz, 1H), 7.75 (s, 1H), 4.51
(q, J = 7.2 Hz, 2H), 1.47 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ 178.2 (CHO), 163.9 (C), 140.2 (CH), 138.6 (C), 138.1
(C), 134.6 (CH), 126.3 (CH), 116.9 (CH), 62.5 (CH2), 60.5 (C),
14.4 (CH3). IR (neat): 3100.3 (w), 2979.5 (w), 1717.2 (s),
1642.2 (s), 1471.4 (m), 1431.6 (s), 1342.7 (s), 1268.3 (s),
1235.5 (s), 1139.2 (s), 1019.2 (s), 764.1 (s), 729.6 (s), 695.8 (m),
612.0 (m) cm−1. LC-MS (ESI): 366.9 (M + Na); HRMS (ESI):
calculated for C11H9N2O3INa 366.9556, found 366.9557
(M + Na, Δ = 0.3 ppm).
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Ethyl 7-iodo-5-nitropyrrolo[1,2-c]pyrimidine-3-carboxylate,
12h. 41%, Mp 150 °C (decomposition). Compound descrip-
tion: brown solid. 1H NMR (400 MHz, CDCl3) δ 9.05 (d, J = 1.4
Hz, 1H), 8.89 (d, J = 1.4 Hz, 1H), 7.79 (s, 1H), 4.52 (q, J = 7.2
Hz, 2H), 1.47 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3)
δ 163.4 (C), 140.0 (CH), 138.9 (C), 132.7 (C), 130.7 (C), 123.5
(CH), 115.1 (CH), 63.1 (C), 62.6 (CH2), 14.3 (CH3). IR (neat):
1699.6 (s), 1486.6 (m), 1406.2 (s), 1296.4 (s), 1276.6 (s),
1215.5 (s), 1012.2 (s), 779.6 (s), 756.3 (s), 598.1 (s) cm−1. LC-MS
(ESI): 361.9 (M + H); HRMS (ESI): calculated for C10H9N3O4I
361.9638, found 361.9633 (M + H, Δ = −1.4 ppm).
Ethyl 5-iodo-7-nitropyrrolo[1,2-c]pyrimidine-3-carboxylate,
12i. 37%, Mp 170 °C (decomposition). Compound description:
bright yellow solid. 1H NMR (400 MHz, CDCl3) δ 10.18 (d, J =
1.2 Hz, 1H), 8.32 (d, J = 1.2 Hz, 1H), 8.07 (s, 1H), 4.55 (q, J =
7.2 Hz, 2H), 1.50 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ 163.4 (C), 138.4 (CH), 138.1 (C), 137.0 (C), 132.4 (C),
126.6 (CH), 117.1 (CH), 62.7 (CH2), 60.9 (C), 14.3 (CH3).
IR (neat): 1712.2 (m), 1505.4 (m), 1436.4 (s), 1381.0 (s), 1313.5
(s), 1282.7 (s), 1211.5 (s), 1020.0 (m), 813.3 (m), 722.6 (s) cm−1.
LC-MS (ESI): 361.9 (M + H); HRMS (ESI): calculated for
C10H9N3O4I 361.9638, found 361.9644 (M + H, Δ = 1.7 ppm).
CCDC 1039440.
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